Generic placeholder image

Current Drug Targets

Author(s): Beppe Calò*, Michele Marchioni, Francesca Sanguedolce, Ugo Giovanni Falagario, Marco Chirico, Giuseppe Carrieri and Luigi Cormio

DOI: 10.2174/1389450121666200802022150

DownloadDownload PDF Flyer Cite As
Neoadjuvant Chemotherapy Before Radical Cystectomy: Why We Must Adhere?

Page: [14 - 21] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Aim: This study provides a critical literature review on state-of-the-art and novel strategies in the field of neoadjuvant treatments for muscle-invasive bladder cancer (MIBC). Methods: A nonsystematic literature review was performed using PubMed, Scopus and Clinical Trials.gov to retrieve papers related to neoadjuvant treatments for MIBC over the past 15 years. Prospective and retrospective studies were included.

Results: Platinum-based treatment is the gold standard and mainly consists of a combination of cisplatin with vinblastine, methotrexate, doxorubicin, gemcitabine, adriamycin or even epirubicin. The 5- year absolute overall survival benefit of MVAC is 5% and the absolute disease-free survival improves by 9%. CMV treatment is associated with a 10-year overall survival improving from 30% to 36% and a 16% reduction in mortality. Gemcitabine and cisplatin regimen provides complete response in 20% of cases, with non-inferior oncological outcomes compared to MVAC regimen. Recent prospective trials investigating neoadjuvant immunotherapy show a high rate of complete response, from 29% with atezolizumab to 39.5% with pembrolizumab. The tyrosine kinase inhibitor pathway is being explored and could offer an interesting strategy to improve survival outcomes.

Conclusion: Available evidence suggests better oncological outcomes for MIBC patients receiving neoadjuvant treatment before radical cystectomy. While MVAC remains the standard of care in cisplatin eligible patients, novel strategies are under development for cisplatin-ineligible patients, whereby immunotherapy seems to hold great promise.

Keywords: Neoadjuvant therapy, bladder cancer, platinum-based therapy, immunotherapy, radical cystectomy, atezolizumab.

Graphical Abstract

[1]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69(1): 7-34.
[http://dx.doi.org//10.3322/caac.21551] [PMID: 30620402]
[2]
Marchioni M, Primiceri G, Ingrosso M, et al. The clinical use of the neutrophil to lymphocyte ratio (nlr) in urothelial cancer: a systematic review. Clin Genitourin Cancer 2016; 14(6): 473-84.
[http://dx.doi.org//10.1016/j.clgc.2016.04.008] [PMID: 27209348]
[3]
Martini A, Sfakianos JP, Renström-Koskela L, et al. The natural history of untreated muscle-invasive bladder cancer. BJU Int 2020; 125(2): 270-5.
[http://dx.doi.org//10.1111/bju.14872] [PMID: 31310696]
[4]
Marchioni M, Nazzani S, Preisser F, Bandini M, Karakiewicz PI. Therapeutic strategies for organ-confined and non-organ-confined bladder cancer after radical cystectomy. Expert Rev Anticancer Ther 2018; 18(4): 377-87.
[http://dx.doi.org//10.1080/14737140.2018.1439744] [PMID: 29429376]
[5]
Flaig TW. Guidelines Updates: Management of Muscle-Invasive Bladder Cancer J Natl Compr Canc Netw 2019; 17(5.5): 591-3.
[6]
Paz-Ares LG, Solsona E, Esteban E, et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol 2010; 28: LBA4518-8.
[http://dx.doi.org//10.1200/jco.2010.28.18_suppl.lba4518]
[7]
Cognetti F, Ruggeri EM, Felici A, et al. Study Group. (†). Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 2012; 23(3): 695-700.
[http://dx.doi.org//10.1093/annonc/mdr354] [PMID: 21859900]
[8]
Sternberg CN, Skoneczna I, Kerst JM, et al. European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d’Etude des Tumeurs Urogénitales; National Cancer Research Institute Bladder Cancer Study Group; NationalCancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 2015; 16(1): 76-86.
[http://dx.doi.org//10.1016/S1470-2045(14)71160-X] [PMID: 25498218]
[9]
Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 2014; 66(1): 42-54.
[http://dx.doi.org//10.1016/j.eururo.2013.08.033] [PMID: 24018020]
[10]
Witjes JA, Bruins M, Cathoimas R, et al. European Association of Urology Guidelines on Muscle-invasive Bladder Cancer - 2019 Eur Urol
[11]
Schiffmann J, Sun M, Gandaglia G, et al. Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study. Can Urol Assoc J 2016; 10(3-4): E82-6.
[http://dx.doi.org//10.5489/cuaj.3292] [PMID: 27330584]
[12]
Schiffmann J, Sun M, Gandaglia G, et al. Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)-medicare database. Minerva Urol Nefrol 2017; 69(2): 173-80.
[PMID: 27733752]
[13]
Sánchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003; 169(1): 110-5.
[http://dx.doi.org//10.1016/S0022-5347(05)64047-5] [PMID: 12478115]
[14]
Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA Jr. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 2003; 170(4 Pt 1): 1085-7.
[http://dx.doi.org//10.1097/01.ju.0000086828.26001.ca] [PMID: 14501697]
[15]
Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak 2007; 7: 16.
[http://dx.doi.org//10.1186/1472-6947-7-16] [PMID: 17573961]
[16]
Prado K, Zhang KX, Pellegrini M, Chin AI. Sequencing of cancer cell subpopulations identifies micrometastases in a bladder cancer patient. Oncotarget 2017; 8(28): 45619-25.
[http://dx.doi.org//10.18632/oncotarget.17312] [PMID: 28487492]
[17]
Kurahashi T, Hara I, Oka N, Kamidono S, Eto H, Miyake H. Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II. Clin Cancer Res 2005; 11(10): 3773-7.
[http://dx.doi.org//10.1158/1078-0432.CCR-04-2297] [PMID: 15897575]
[18]
Sonpavde Guru, et al. ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. Future Oncology 2019
[19]
Sonpavde G, Sternberg CN. Neoadjuvant systemic therapy for urological malignancies. BJU Int 2010; 106(1): 6-22.
[http://dx.doi.org//10.1111/j.1464-410X.2010.09425.x] [PMID: 20553475]
[20]
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48(2): 202-5.
[http://dx.doi.org//10.1016/j.eururo.2005.04.006] [PMID: 15939524]
[21]
Galsky MD, Pal SK, Chowdhury S, et al. Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 2015; 121(15): 2586-93.
[http://dx.doi.org//10.1002/cncr.29387] [PMID: 25872978]
[22]
Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29(16): 2171-7.
[http://dx.doi.org//10.1200/JCO.2010.32.3139] [PMID: 21502557]
[23]
Yin M, Joshi M, Meijer RP, et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist 2016; 21(6): 708-15.
[http://dx.doi.org//10.1634/theoncologist.2015-0440] [PMID: 27053504]
[24]
Sternberg CN, de Mulder P, Schornagel JH, et al. EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42(1): 50-4.
[http://dx.doi.org//10.1016/j.ejca.2005.08.032] [PMID: 16330205]
[25]
Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014; 32(18): 1889-94.
[http://dx.doi.org//10.1200/JCO.2013.52.4785] [PMID: 24821883]
[26]
Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 2014; 32(18): 1895-901.
[http://dx.doi.org//10.1200/JCO.2013.53.2465] [PMID: 24821881]
[27]
Peyton CC, Tang D, Reich RR, et al. Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer. JAMA Oncol 2018; 4(11): 1535-42.
[http://dx.doi.org//10.1001/jamaoncol.2018.3542] [PMID: 30178038]
[28]
Scosyrev E, Messing EM, van Wijngaarden E, et al. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer 2012; 118(1): 72-81.
[http://dx.doi.org//10.1002/cncr.26238] [PMID: 21720989]
[29]
Iyer G, Balar AV, Milowsky MI, et al. Multicenter prospective phase ii trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer. J Clin Oncol 2018; 36(19): 1949-56.
[http://dx.doi.org//10.1200/JCO.2017.75.0158] [PMID: 29742009]
[30]
Dash A, Pettus JA IV, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008; 113(9): 2471-7.
[http://dx.doi.org//10.1002/cncr.23848] [PMID: 18823036]
[31]
Okabe K, Shindo T, Maehana T, et al. Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study. Jpn J Clin Oncol 2018; 48(10): 934-41.
[http://dx.doi.org//10.1093/jjco/hyy122] [PMID: 30169681]
[32]
Zargar H, Shah JB, van Rhijn BW, et al. Collaborators. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. J Urol 2018; 199(6): 1452-8.
[http://dx.doi.org//10.1016/j.juro.2017.12.062] [PMID: 29329894]
[33]
Wahafu W, Liu S, Xu W, et al. The long-term efficacy of one-shot neoadjuvant intra-arterial chemotherapy combined with radical cystectomy versus radical cystectomy alone for bladder cancer: a propensity-score matching study. BMC Urol 2019; 19(1): 117.
[http://dx.doi.org//10.1186/s12894-019-0552-7] [PMID: 31733646]
[34]
Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 2006; 24(3): 296-304.
[http://dx.doi.org//10.1007/s00345-006-0061-7] [PMID: 16518661]
[35]
Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 2012; 61(5): 1039-47.
[http://dx.doi.org//10.1016/j.eururo.2012.02.028] [PMID: 22381169]
[36]
Hautmann RE, de Petriconi RC, Volkmer BG. Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol 2010; 184(3): 990-4.
[http://dx.doi.org//10.1016/j.juro.2010.05.037] [PMID: 20643429]
[37]
Morgan TM, Barocas DA, Keegan KA, et al. Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol 2012; 188(6): 2139-44.
[http://dx.doi.org//10.1016/j.juro.2012.08.042] [PMID: 23083864]
[38]
Porter MP, Gore JL, Wright JL. Hospital volume and 90-day mortality risk after radical cystectomy: a population-based cohort study. World J Urol 2011; 29(1): 73-7.
[http://dx.doi.org//10.1007/s00345-010-0626-3] [PMID: 21132553]
[39]
Nielsen ME, Mallin K, Weaver MA, et al. Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base. BJU Int 2014; 114(1): 46-55.
[http://dx.doi.org//10.1111/bju.12566] [PMID: 24219110]
[40]
Gandaglia G, et al. The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: A population-based study. Eur Urol 2014; 66: 561-8.
[http://dx.doi.org//10.1016/j.eururo.2014.01.014]
[41]
Tyson MD II, Bryce AH, Ho TH, Carballido EM, Castle EP. Perioperative complications after neoadjuvant chemotherapy and radical cystectomy for bladder cancer. Can J Urol 2014; 21(3): 7259-65.
[PMID: 24978354]
[42]
Aldhaam NA, Elsayed AS, Jing Z, et al. Neoadjuvant Chemotherapy is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Use from the IRCC. J Urol 2020; 203(1): 57-61.
[http://dx.doi.org//10.1097/JU.0000000000000445] [PMID: 31600114]
[43]
Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 2017; 18(12): e731-41.
[http://dx.doi.org//10.1016/S1470-2045(17)30607-1] [PMID: 29208439]
[44]
Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004; 173(2): 945-54.
[http://dx.doi.org//10.4049/jimmunol.173.2.945] [PMID: 15240681]
[45]
Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 2019; 25(11): 1706-14.
[http://dx.doi.org//10.1038/s41591-019-0628-7] [PMID: 31686036]
[46]
Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study. J Clin Oncol 2018; 36(34): 3353-60.
[http://dx.doi.org//10.1200/JCO.18.01148] [PMID: 30343614]
[47]
Briganti A, Gandaglia G, Scuderi S, et al. Surgical safety of radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab in patients with bladder cancer: Prospective assessment of perioperative outcomes from the PURE-01 Trial. Eur Urol 2020; 77(5): 576-80.
[http://dx.doi.org//10.1016/j.eururo.2019.12.019] [PMID: 31911010]
[48]
Hoimes C, et al. LBA33A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC). Ann Oncol 2018.29.
[49]
Martinez Chanza N, et al. Avelumab as neoadjuvant therapy in subjects with muscle-invasive urothelial carcinoma (AURA trial). J Clin Oncol 2018; 36: TPS535--5.
[http://dx.doi.org//10.1200/JCO.2018.36.6_suppl.TPS535]
[50]
Valsecchi ME. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(13): 1270-1.
[http://dx.doi.org//10.1056/NEJMc1509660] [PMID: 26398077]
[51]
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019; 381(16): 1535-46.
[http://dx.doi.org//10.1056/NEJMoa1910836] [PMID: 31562797]
[52]
Cormio L, Tolve I, Annese P, et al. Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Res 2009; 29(10): 4201-4.
[PMID: 19846973]
[53]
Cormio L, Tolve I, Annese P, et al. Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer. Urol Oncol 2010; 28(3): 285-9.
[http://dx.doi.org//10.1016/j.urolonc.2008.08.003] [PMID: 18976938]
[54]
Sanguedolce F, Bufo P, Carrieri G, Cormio L. Predictive markers in bladder cancer: do we have molecular markers ready for clinical use? Crit Rev Clin Lab Sci 2014; 51(5): 291-304.
[http://dx.doi.org//10.3109/10408363.2014.930412] [PMID: 25036341]
[55]
Cormio A, Sanguedolce F, Musicco C, et al. Mitochondrial dysfunctions in bladder cancer: Exploring their role as disease markers and potential therapeutic targets. Crit Rev Oncol Hematol 2017; 117: 67-72.
[http://dx.doi.org//10.1016/j.critrevonc.2017.07.001] [PMID: 28807237]
[56]
Cormio L, Sanguedolce F, Cormio A, et al. Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer. Oncotarget 2017; 8(15): 25433-41.
[http://dx.doi.org//10.18632/oncotarget.15989] [PMID: 28445991]
[57]
Sanguedolce F, Brunelli M, D’amuri A, et al. Evolving concepts and use of immunohistochemical biomarkers in flat non-neoplastic urothelial lesions: WHO 2016 classification update with diagnostic algorithm. Biomarkers 2018; 23(4): 305-14.
[http://dx.doi.org//10.1080/1354750X.2018.1428360] [PMID: 29334244]
[58]
Sanguedolce F, Cormio A, Massenio P, et al. Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer. J Cancer Res Clin Oncol 2018; 144(4): 637-44.
[http://dx.doi.org//10.1007/s00432-018-2593-9] [PMID: 29362915]
[59]
Culp SH, Dickstein RJ, Grossman HB, et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol 2014; 191(1): 40-7.
[http://dx.doi.org//10.1016/j.juro.2013.07.061] [PMID: 23911605]
[60]
Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63(19): 6221-8.
[PMID: 14559807]
[61]
Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer Annals of oncology :official journal of the European Society for Medical Oncology / ESMO 2011; 22: 139-44.
[http://dx.doi.org/10.1093/annonc/mdq333]
[62]
Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy Annals of oncology : official journal of the European Society for Medical Oncology/ ESMO 2007; 18: 522-8.
[http://dx.doi.org/10.1093/annonc/mdl435]
[63]
Hoffmann AC, Wild P, Leicht C, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010; 12(8): 628-36.
[http://dx.doi.org//10.1593/neo.10402] [PMID: 20689757]
[64]
Olaussen KA, Dunant A, Fouret P, et al. IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355(10): 983-91.
[http://dx.doi.org//10.1056/NEJMoa060570] [PMID: 16957145]
[65]
Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014; 4(10): 1140-53.
[http://dx.doi.org//10.1158/2159-8290.CD-14-0623] [PMID: 25096233]
[66]
Groenendijk FH, de Jong J, Fransen van de Putte EE, et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 2016; 69(3): 384-8.
[http://dx.doi.org//10.1016/j.eururo.2015.01.014] [PMID: 25636205]
[67]
Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014; 25(2): 152-65.
[http://dx.doi.org//10.1016/j.ccr.2014.01.009] [PMID: 24525232]
[68]
Tse J, Ghandour R, Singla N, Lotan Y. Molecular predictors of complete response following neoadjuvant chemotherapy in urothelial carcinoma of the bladder and upper tracts. Int J Mol Sci 2019; 20(4): 793.
[http://dx.doi.org//10.3390/ijms20040793] [PMID: 30781730]
[69]
Flaig TW, et al. SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer. J Clin Oncol 2019; 37: 4506-6.
[http://dx.doi.org//10.1200/JCO.2019.37.15_suppl.4506]
[70]
Necchi A, Madison R, Chung J, et al. 905PD Multiple-cohort analysis investigating FGFR3 alteration as a predictor of nonresponse to neoadjuvant pembrolizumab (pembro) in muscleinvasive bladder 2019.academic.oup.com
[71]
Buttigliero C, Tucci M, Vignani F, Scagliotti GV, Di Maio M. Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. Cancer Treat Rev 2017; 54: 1-9.
[http://dx.doi.org//10.1016/j.ctrv.2017.01.002] [PMID: 28135623]